XMAS Shopping Online:
1) If you buy from Amazon, please go to the OMSTC website and click the logo at the top of the page.
2) For any other retailers go to easyfundraising
It really does help us and it costs you nothing.
Tysabri unsuccessful in secondary progressive MS trial
Source MS Trust:
Preliminary results announced in a press release (link is external) report that treatment with Tysabri did not slow down the gradual increase in disability experienced by people with secondary progressive MS. Read on.
Preliminary results announced in a press release (link is external) report that treatment with Tysabri did not slow down the gradual increase in disability experienced by people with secondary progressive MS. Read on.
Progressive MS receives latest funding boost
Source MS Society:
Eleven projects have received funding in the next step to find the most promising collaborative progressive MS research projects in the world. The progressive MS Alliance is a growing global collaboration committed to speeding up the development of treatment for progressive MS. Read on.
Eleven projects have received funding in the next step to find the most promising collaborative progressive MS research projects in the world. The progressive MS Alliance is a growing global collaboration committed to speeding up the development of treatment for progressive MS. Read on.
Multiple sclerosis patient walks after taking HIV drugs
Source BBC:
A woman with multiple sclerosis (MS) says her symptoms improved so dramatically she was able to walk again after being prescribed HIV drugs.
Shana Pezaro, 36, from Hove, East Sussex, was given antiretroviral drugs after fearing she may have contracted HIV. Read on.
MS Society local branch newsletter Nov/Dec 2015
ECTRIMS 2015 round up
Source MS Trust
ECTRIMS (European Committee for Treatment and Research In Multiple Sclerosis) hosts the world’s largest conference devoted to basic and clinical research in MS.
This year’s meeting took place in Barcelona from 7-10 October and featured a wide range of presentations, posters and reports of new and on-going research. Read on.
Biogen says multiple sclerosis drug trial for Natalizumab was unsuccessful.
Source Market Watch
Biogen Inc. said Wednesday that a late-stage trial of a drug to treat of secondary progressive multiple sclerosis was unsuccessful. The trial of Natalizumab found that the drug was “well-tolerated” by patients but did not meet its primary and secondary endpoints. “While we’re disappointed with these results, we believe this research will provide the MS community important insights into this more advanced patient population,” said Alfred Sandrock, group senior vice president and chief medical officer at Biogen, in the press release. Shares of Biogen rose 10% Wednesday after the company beat third-quarter earnings expectations
Biogen Inc. said Wednesday that a late-stage trial of a drug to treat of secondary progressive multiple sclerosis was unsuccessful. The trial of Natalizumab found that the drug was “well-tolerated” by patients but did not meet its primary and secondary endpoints. “While we’re disappointed with these results, we believe this research will provide the MS community important insights into this more advanced patient population,” said Alfred Sandrock, group senior vice president and chief medical officer at Biogen, in the press release. Shares of Biogen rose 10% Wednesday after the company beat third-quarter earnings expectations
Study on Biotin for Secondary and Primary Progressive Forms of Multiple Sclerosis
Dr. Daniel Kantor talks about the MD1003 Trial analysis on Biotin for Secondary and Primary Progressive Multiple Sclerosis. Watch here.
Want to take part in a clinical trial?
Note: For people with relapsing remitting MS or Secondary progressive MS only.
Want to take part in a clinical trial? In recognition of your time involved in this study you will receive £1,250 and all your travel needs will be organised by Trials4Us. BMSTC will also receive a donation.
Trials4Us are carrying out an important clinical trial of a new treatment for people with RFMS. This is a validation study to check that a particular imaging technique works.
There are no expected benefits to you from participation in this study, it is purely for research purposes. However, by taking part in this study, you may be helping future patients by contributing to medical knowledge about RFMS. Find out more here.
Christmas Lunch – 16th December
Christmas Lunch, Wednesday 16th December, 12.30 prompt, Park Place Brasserie, Milton Park, 3 courses £18 including tip. Please let reception know if you would like to come and your choice of food please.
Menu:
Starters:
Prawn and Avocado Salad with lime and chilli dressing
Soup of the Day
Stilton, Walnut and Caramelised Pear Salad
(all served with selection of mini bread rolls)
Main Courses:
Roast Turkey Crown with all Traditional Trimmings
Navarin of Lamb (slow Braised Lamb Fillet in a light red wine jus)
Grilled Fillet of Cod with Crispy Chorizo, Steamed Spinach and Cauliflower Puree
Wild Mushroom Risotto with Parmesan and Rocket
(all served with selection of seasonal vegetables, roast & baby potatoes)
Puddings:
Xmas Pudding with Brandy Butter
Citron Tarte with Steamed Ginger Cream
Chocolate Mint Parfait
Filter coffee and Mince Pies
